• Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; S. 4348, FDASLA Act of 2022; The Cannabis Administration and Opportunity Act (discussion draft); H.R.2617, Consolidated Appropriations Act, 2023.

Duration: March 12, 2019 to March 31, 2023

General Issues: Health Issues

Spending: about $1,040,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2019: U.S. Senate, House of Representatives

Related Foreign Entities: GW Pharmaceuticals plc (Cambridge, CB24 9BZ, GBR); contribution to lobbying: $0; ownership 100%